Intellipharmaceutics International Inc.
IPCIQ
$0.00
$0.000.00%
OTC PK
| 08/31/2023 | 05/31/2023 | 02/28/2023 | 11/30/2022 | 08/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 259.69% | -- | 391.42% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 259.69% | -- | 291.25% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -4,314.66% | -- | 291.25% | -- | -- |
| SG&A Expenses | 166.20% | -61.60% | -46.80% | -4.09% | -199.02% |
| Depreciation & Amortization | -21.17% | -21.36% | -20.97% | -21.10% | -21.25% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 381.73% | -59.13% | -26.70% | -65.84% | -64.45% |
| Operating Income | -388.09% | 97.49% | 61.00% | 67.91% | 66.21% |
| Income Before Tax | -538.24% | 93.56% | 59.63% | 58.01% | 76.59% |
| Income Tax Expenses | -- | -- | -- | 104.64% | -- |
| Earnings from Continuing Operations | -538.24% | 93.56% | 59.63% | 55.28% | 76.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -538.24% | 93.56% | 59.63% | 55.28% | 76.59% |
| EBIT | -388.09% | 97.49% | 61.00% | 67.91% | 66.21% |
| EBITDA | -455.04% | 100.77% | 63.85% | 71.21% | 69.10% |
| EPS Basic | -541.57% | 93.70% | 59.77% | 69.04% | 76.70% |
| Normalized Basic EPS | -537.50% | 96.05% | 59.64% | 82.06% | 76.57% |
| EPS Diluted | -500.00% | 93.33% | 64.33% | 68.88% | 75.00% |
| Normalized Diluted EPS | -537.50% | 96.05% | 59.64% | 82.06% | 76.57% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 44.29% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 44.29% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |